Navigation Links
Reportlinker Adds Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)
Date:4/20/2011

NEW YORK, April 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)

http://www.reportlinker.com/p0483050/Zolpidem----Key-patent-SPC-and-data-exclusivity-expiry-44-country-coverage.html

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Zolpidem

Zolpidem indications: Short-term treatment of insomnia

Zolpidem innovator: Sanofi Aventis (Dormizol, Stilnox, Stilnoxium, Ivadal, Stilnoct, Ambien); Novadel (Zolpimist); Meda (Edluar)

Examples of information found in this online report include:

- Includes key patent publications for 44 countries (see list below)

- Contains SPC protection for every EU state plus patent term extensions in other countries

- Data exclusivity calculated on a country by country basis

- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product

- DMF & Paragraph IV filings

- Litigation alerts

- Marketing authorisation holders in selected territories

- Patent risk analysis via graphical display of data from patent filings

- Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

Country Region Extensions

Australia Asia-Pacific S70

Canada Americas N/A

USA Americas S156

Germany Western Europe SPC

Great Britain Western Europe SPCS

France Western Europe NAT/SPC

Spain Western Europe SPC

South Africa Africa N/A

China Asia-Pacific N/A

Japan Asia-Pacific S67

New Zealand Asia-Pacific N/A

Bosnia & Herzegovina Balkan N/A

Bulgaria Balkan SPC

Croatia Balkan N/A

Romania Balkan SPC

Slovenia Balkan NAT/SPC

Estonia Baltic NAT/SPC

Lithuania Baltic NAT/SPC

Latvia Baltic NAT/SPC

Czech Republic Central Europe NAT/SPC

Hungary Central Europe SPC

Poland Central Europe SPC

Slovakia Central Europe NAT/SPC

Serbia & Montenegro Central Europe N/A

Cyprus Mediterranean NAT/SPC

Greece Mediterranean SPC

Israel Mediterranean NAT

Malta Mediterranean SPC

Turkey Mediterranean N/A

Denmark Scandinavia SPC

Finland Scandinavia SPC

Iceland Scandinavia SPC

Norway Scandinavia SPC

Sweden Scandinavia SPC

Brazil South America N/A

Mexico South America N/A

Austria Western Europe SPC

Belgium Western Europe SPC

Switzerland Western Europe NAT/SPC

Ireland Western Europe SPC

Italy Western Europe NAT/SPC

Luxembourg Western Europe SPC

The Netherlands Western Europe SPC

Portugal Western Europe SPC

Other key information contained in the report:

- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countriest**.

- News articles

- Litigation alerts

- Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.

- US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.

- Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.

- 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.

*Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Developer report).

**General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

***Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Developer comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Developer reports.

Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

- Includes key patent publications for 44 countries

- Contains SPC protection for every EU state plus patent term extensions in other countries

- Data exclusivity calculated on a country by country basis

- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product

- DMF & Paragraph IV filings

- Litigation alerts

- Marketing authorisation holders in selected territories

- Patent risk analysis via graphical display of data from patent filings

- Hyper-linking to crucial patent documents and national registries enabling data verification

To order this report:

: Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):